Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile 

Orcid

Education 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile 

Education 

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience 

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards 

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus 

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Dipanjan Karati | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dipanjan Karati | Drug Discovery and Development | Best Researcher Award

Dr Dipanjan Karati, Techno India University, West Bengal, India

Dr. Dipanjan Karati is an Assistant Professor at Techno India University, West Bengal, with expertise in pharmaceutical chemistry. He holds a M. Pharm (2021) from Bharati Vidyapeeth University and a B. Pharm (2019) from MAKAUT, both with distinction. His research focuses on neurodegenerative diseases and antimicrobial agents, with several publications in prestigious journals. Dr. Karati has actively participated in numerous seminars, webinars, and workshops. He is a GPAT 2019 qualifier and has industrial training at Glenmark Pharmaceuticals. He is passionate about academics and research in the field of drug development. 📚💊🧠🔬👨‍🔬

Publication Profile

Google Scholar

Academic Excellence

Dr. Dipanjan Karati is a highly qualified pharmaceutical professional with a strong academic background. He completed his M. Pharm in Pharmaceutical Chemistry from Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, in 2021, securing a first-class distinction with an 8.09 CGPA. Prior to that, he earned his B Pharm from NSHM Knowledge Campus, Kolkata, in 2019, with an outstanding 80.2% (1st class with distinction). Dr. Karati completed his HSC in 2013 with 81.2% and SSC in 2011 with 78.125% from Garh Bhawanipur RP Institution, Howrah. His consistent academic performance highlights his dedication to the pharmaceutical field. 📚💊🎓

Research Project

Dr. Dipanjan Karati’s research focuses on the “In Silico Design, Synthesis, and Evaluation of Novel Schiff Base Congeners as Neurodegenerative and Antimicrobial Agents.” His objective is to design and synthesize innovative pyrimidine derivatives containing a nitrile group and substituted Schiff bases with azomethine groups. These compounds are being explored for their potential in treating neurodegenerative diseases and exhibiting antimicrobial properties. Dr. Karati’s work combines advanced computational techniques and experimental synthesis to develop effective therapeutic agents, aiming to contribute significantly to the fields of neurodegenerative diseases and antimicrobial resistance. 🔬🧠💊🦠💡

Experience

Dr. Dipanjan Karati has an impressive academic and professional background in the pharmaceutical field. He completed his Industrial Training at Glenmark Pharmaceutical Limited from January 9th to 23rd, 2018, gaining valuable industry experience. He served as an Assistant Professor at Gitanjali College of Pharmacy in Lohapur, Birbhum, for one year, contributing to the academic development of students. Currently, Dr. Karati holds the position of Assistant Professor at the School of Pharmacy, TIU, since September 2022, continuing his dedication to education and research. 📚💊👨‍🏫

Achievements and Awards

Dr. Dipanjan Karati achieved a significant milestone by qualifying for the All India Graduate Pharmacy Aptitude Test (GPAT) in 2019, showcasing his dedication and expertise in the field of pharmacy. 🏆📚 This prestigious achievement highlights his academic excellence and potential for contributing to pharmaceutical sciences. 🌟💊 With his strong foundation and passion for research, Dr. Karati is committed to advancing innovations in pharmacy and healthcare. 🚀🔬 His GPAT qualification is a testament to his hard work and determination, inspiring others in the field to strive for academic and professional success. 🌱🎓

Research Focus

Dr. Dipanjan Karati’s research focuses on medicinal chemistry, pharmacognosy, and drug discovery. His studies emphasize exploring bioactive compounds from plants 🌱, such as Ficus racemosa and Zingiber officinale, for their pharmacological properties including anti-inflammatory, anticancer, and antimicrobial activities 🧪🩺. He investigates synthetic scaffolds like pyrazoles and benzimidazoles for designing innovative therapies targeting diseases such as cancer, malaria, and infections 🎯🧬. Dr. Karati also explores bio-responsive polymers for targeted drug delivery and examines natural products like Cordyceps sinensis for therapeutic potential 🍄🔬. His work bridges natural products and modern medicinal approaches, advancing personalized treatments 🌟📖.

Publication Top Notes

Alkylating agents, the road less traversed, changing anticancer therapy

Pyrazole Scaffolds: centrality in anti-inflammatory and antiviral drug design

Exploring the pharmacognostic properties and pharmacological activities of phytocompounds present in Ficus racemosa linn.: A concise review

A molecular insight into pyrazole congeners as antimicrobial, anticancer, and antimalarial agents

Plant Bioactives in the Treatment of Inflammation of Skeletal Muscles: A Molecular Perspective

In-silico investigation and drug likeliness studies of benzimidazole congeners: the new face of innovation

Exploring the phytochemistry, pharmacognostic properties, and pharmacological activities of medically important plant Momordica charantia